6.10
2.71%
-0.17
After Hours:
6.10
Pluri Inc stock is currently priced at $6.10, with a 24-hour trading volume of 12,481.
It has seen a -2.71% decreased in the last 24 hours and a +17.99% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $6.27 pivot point. If it approaches the $6.00 support level, significant changes may occur.
Previous Close:
$6.27
Open:
$6.48
24h Volume:
12,481
Market Cap:
$32.87M
Revenue:
$254.00K
Net Income/Loss:
$-27.16M
P/E Ratio:
-7.9221
EPS:
-0.77
Net Cash Flow:
$-21.40M
1W Performance:
+4.90%
1M Performance:
+17.99%
6M Performance:
+913.29%
1Y Performance:
+626.28%
Pluri Inc Stock (PLUR) Company Profile
Name
Pluri Inc
Sector
Industry
Phone
972 74 710 8600
Address
Building No. 5, MATAM Advanced Technology Park, Haifa
Pluri Inc Stock (PLUR) Latest News
How to Take Advantage of moves in (PLUR) - Stock Traders Daily
Stock Traders Daily
Pluri Third Quarter 2024 Earnings: US$1.01 loss per share (vs US$1.53 loss in 3Q 2023) - Yahoo Finance
Yahoo Finance
Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment
GlobeNewswire Inc.
Pluri Unveils Proprietary 3D Cell Expansion Technology - Contract Pharma
Contract Pharma
Pluri’s Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences
GlobeNewswire Inc.
Pluri announces 1-for-8 reverse stock split - TipRanks.com - TipRanks
TipRanks
Pluri Inc Stock (PLUR) Financials Data
Pluri Inc (PLUR) Revenue 2024
PLUR reported a revenue (TTM) of $254.00 thousand for the quarter ending September 30, 2023.
Pluri Inc (PLUR) Net Income 2024
PLUR net income (TTM) was -$27.16 million for the quarter ending September 30, 2023, a +24.41% increase year-over-year.
Pluri Inc (PLUR) Cash Flow 2024
PLUR recorded a free cash flow (TTM) of -$21.40 million for the quarter ending September 30, 2023, a +40.00% increase year-over-year.
Pluri Inc (PLUR) Earnings per Share 2024
PLUR earnings per share (TTM) was -$0.70 for the quarter ending September 30, 2023, a +37.50% growth year-over-year.
About Pluri Inc
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the muscle recovery following surgery for hip fracture; and Phase I/II clinical trial for the treatment of steroid-refractory graft versus host disease in collaboration with Tel Aviv Sourasky Medical Center, as well as completed a Phase II clinical trial for the treatment of acute respiratory distress syndrome associated with COVID-19 and a Phase I clinical trial for incomplete recovery following bone marrow transplantation. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation; and a solution for the treatment of acute radiation syndrome through its collaboration in the United States with the National Institutes of Health and the U.S. Department of Defense. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Cap:
|
Volume (24h):